DOASENSE GmbH -- Home - Pioneering Point-of-Care Testing for DOACs

Go to content
Pioneering Novel Approaches to Testing for DOACs
NEWS FLASH:
    • 2018-05:   The International Council for Standardization in Haematology (ICSH) has included DOASENSE's DOAC Dipstick test in its 2018 Recommendations for Laboratory Measurement of Direct Oral Anticoagulants [ICSH Guidelines]

    • 2018-04:    We have started the controlled launch of our DOAC Dipstick test with select clinics in Germany.

    • 2018-03:   Join us at these upcoming conferences and trade shows, where DOASENSE will be present with a booth:
              • DGK 2018, Mannheim (Germany) - April 4-7 - Annual Meeting of the German Cardiac Society
              • ISTH-SSC 2018, Dublin (Ireland) - July 18-21 - SSC Meeting of the International Society of Thrombosis and Haemostasis
              • ESC 2018, Munich (Germany) - August 25-29 - Congress of the European Society of Cardiology

    • 2018-02:   DOASENSE's exhibit at the 62nd Annual Meeting of the Society of Thrombosis and Hemostasis Research (GTH 2018) in Vienna received broad interest from the attending community


    • 2018-01:   Our patented DOAC Dipstick Product received the CE Mark

    • 2017-12:   The Management System of DOASENSE GmbH has been approved by LRQA to the following standards: ISO 13485:2016  [Certificate of Approval]

    • 2017-08:   DOASENSE press release on presentation of first-ever Point-of-Care urine test for Direct Oral Anticoagulants (DOACs)  [Read more]

    • 2017-07:   DOASENSE is proud BRONZE SPONSOR of the ISTH 2017 in Berlin



When every minute counts …
  … fast DOAC testing matters.

DOASENSE’s mission objective is changing the landscape of testing for DOACs (new synthetic oral anticoagulants) with novel & quick point of care urine tests

ER Situation
A rapid assessment of the anticoagulant effect of non-vitamin K antagonist oral anticoagulants (Direct Oral AntiCoagulants – DOACs) by point of care testing (POCT) is an unmet clinical need:
- in specific patient populations, or under certain clinical circumstances
- for confirmation of compliance

The determination of DOACs has long been limited to blood sampling approaches, with all their potential limitations.

DOASENSE develops products for specific testing for DOACs in urine

Tests which are easy to use and easy to interpret, reproducible, and patient friendly

Listen to what opinion leaders think about DOASENSE's solutions:
Typical clinical scenarios where testing for specific DOACs can be of value

    • Stroke (e.g. before thrombolytic therapy)
    • Trauma
    • Emergency procedures
    • Evaluating for venous thromboembolism
    • Spontaneous hemorrhage
    • General surgery or invasive procedures (e.g. dental surgery)
    • Other situations where medication history may not available

In each of these situations the objective is establishing the absence of DOACs in the patient prior to procedure
Divider
NOTE: DOASENSE(TM) products may not be available or approved in your country.


Copyright (c) 2016-2018 DOASENSE GmbH. All rights reserved.
Back to content